To register a new drug in Taiwan, companies must conduct preclinical and clinical trials, submit a New Drug Application (NDA) with relevant clinical and manufacturing data to the Taiwan Food and Drug Administration (TFDA), undergo a detailed review, possibly benefit from accelerated approval for priority drugs, and maintain compliance through post-market monitoring and license renewals.
